Insider · CIK 0001857670

Curley Joanne

Reports to the SEC for 2 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001857670

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-09-09	VTGNVistagen Therapeutics, Inc. · Non-Qualified Stock Option (right to buy)A Award	Director	AAward	+17.6K sh	—	—	17,600
2024-09-06	VTGNVistagen Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+14.1K sh	—	—	14,100
2024-03-04	VTGNVistagen Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+12.5K sh	—	—	12,500
2023-08-21	VERAVera Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−1,490 sh	$16.66	−$24.8K	26,962
2023-02-15	VERAVera Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Development Officer	AAward	+150K sh	—	—	150,000
2022-12-16	VERAVera Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−1,429 sh	$19.12	−$27.3K	26,821
2022-12-16	VERAVera Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+1,429 sh	$2.90	+$4,139.527	28,250
2022-12-16	VERAVera Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−783 sh	$20.17	−$15.8K	26,821
2022-12-16	VERAVera Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+783 sh	$2.90	+$2,268.194	27,604
2022-12-16	VERAVera Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−2,212 sh	—	—	35,801
2022-12-13	VERAVera Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−11.7K sh	$18.28	−$214K	26,821
2022-12-13	VERAVera Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+11.7K sh	$11.00	+$129K	38,554
2022-12-13	VERAVera Therapeutics, Inc. · Stock Options (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−1,078 sh	—	—	8,639
2022-12-13	VERAVera Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−11.7K sh	—	—	65,384
2022-12-13	VERAVera Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+1,078 sh	$6.37	+$6,869.878	27,899
2022-12-13	VERAVera Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−1,078 sh	$18.19	−$19.6K	26,821
2022-12-12	VERAVera Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+6,900 sh	$11.00	+$75.9K	33,721
2022-12-12	VERAVera Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−6,900 sh	$18.25	−$126K	26,821
2022-12-12	VERAVera Therapeutics, Inc. · Stock Options (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−6,900 sh	—	—	77,117
2022-12-07	VERAVera Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−494 sh	$16.47	−$8,136.18	26,821
2022-11-17	VERAVera Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−2,211 sh	$15.84	−$35K	27,315
2022-11-17	VERAVera Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−1,078 sh	—	—	9,717
2022-11-17	VERAVera Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+2,211 sh	$2.90	+$6,404.825	29,526
2022-11-17	VERAVera Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−2,211 sh	—	—	38,013
2022-11-17	VERAVera Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−1,078 sh	$15.86	−$17.1K	27,315
2022-11-17	VERAVera Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+1,078 sh	$6.37	+$6,869.878	28,393
2022-11-09	VERAVera Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−494 sh	$16.54	−$8,170.76	27,315
2022-10-18	VERAVera Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−5,298 sh	$19.42	−$103K	27,809
2022-10-18	VERAVera Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+5,298 sh	$11.00	+$58.3K	33,107
2022-10-18	VERAVera Therapeutics, Inc. · Stock Options (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−5,300 sh	—	—	84,017
2022-10-18	VERAVera Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−1,078 sh	$19.43	−$20.9K	27,809
2022-10-18	VERAVera Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−2,212 sh	—	—	40,224
2022-10-18	VERAVera Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−2,212 sh	$19.39	−$42.9K	27,809
2022-10-18	VERAVera Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−1,078 sh	—	—	10,795
2022-10-18	VERAVera Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−2 sh	$20.30	−$40.6	27,809
2022-10-18	VERAVera Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+1,078 sh	$6.37	+$6,869.878	28,887
2022-10-18	VERAVera Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+2 sh	$11.00	+$22	27,811
2022-10-18	VERAVera Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+2,212 sh	$2.90	+$6,407.722	30,021
2022-10-05	VERAVera Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−988 sh	$21.64	−$21.4K	27,809
2022-09-21	VERAVera Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−910 sh	$21.13	−$19.2K	28,797
2022-09-21	VERAVera Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+264 sh	$11.00	+$2,904	29,061
2022-09-21	VERAVera Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+910 sh	$11.00	+$10K	29,707
2022-09-21	VERAVera Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−264 sh	$22.35	−$5,899.476	28,797
2022-09-21	VERAVera Therapeutics, Inc. · Stock Options (right to buy)M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	−1,174 sh	—	—	89,317
2022-09-20	VERAVera Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+10.1K sh	$11.00	+$111K	38,909
2022-09-20	VERAVera Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−10.1K sh	$20.80	−$210K	28,797
2022-09-20	VERAVera Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+978 sh	$6.37	+$6,232.598	29,775
2022-09-20	VERAVera Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−978 sh	$20.54	−$20.1K	28,797
2022-09-20	VERAVera Therapeutics, Inc.M Exercise/Conversion	Chief Development Officer	MExercise/Conversion	+1,828 sh	$2.90	+$5,295.35	30,625
2022-09-20	VERAVera Therapeutics, Inc.S Sale	Chief Development Officer	SSale	−1,828 sh	$20.48	−$37.4K	28,797

Recent filings

Accepted (ET)
Sep 114
Curley Joanne0001411685-25-000075
SEC(opens sec.gov)
Sep 104
Curley Joanne0001415889-24-023147
SEC(opens sec.gov)
Mar 64
Curley Joanne0001415889-24-007096
SEC(opens sec.gov)
Aug 234
Curley Joanne0001209191-23-047103
SEC(opens sec.gov)
Feb 174
Curley Joanne0001209191-23-010542
SEC(opens sec.gov)
Dec 194
Curley Joanne0001209191-22-061973
SEC(opens sec.gov)
Dec 144
Curley Joanne0001209191-22-061178
SEC(opens sec.gov)
Dec 84
Curley Joanne0001209191-22-060331
SEC(opens sec.gov)

Companies

Address

C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVE

SOUTH SAN FRANCISCO, CA, 94080